/
Immunology
Immune System Disease
29
Pipeline Programs↗
1
Active Trials↗
14
Companies Involved↗
Immune System Disease is an emerging landscape with 29 programs across 14 companies. The most active players are Bristol-Myers Squibb, AbbVie, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
69%
Monoclonal antibody
20 of 29 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.
Analysis
Trial Status
1
clinical trials
Recruiting1 · 100%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)